Delivery Order SPE2DB22D2006-SPE2DB25FW2FQ
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on July 16, 2025, for the supply of Rabavert rabies vaccine with diluents. This firm fixed price delivery order, valued at $62,874.00, is scheduled for completion by July 17, 2025, and represents a non-set-aside competitive award. The contract will be performed at the company's corporate office location in Conshohocken,...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $2,095.80 by the Defense Logistics Agency for the supply of Rabavert rabies vaccine with diluents. This contract, issued on August 25, 2025, with an ultimate completion date of August 26, 2025, represents a firm fixed-price transaction with no set-aside designation. The award was competitively procured and reflects AmerisourceBergen's ongoing...
- AmerisourceBergen Drug Corp received a delivery order award on July 17, 2025, from the Defense Department's Medical Supply Chain for Rabavert rabies vaccine with diluents, valued at $4,406.01. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 18, 2025, and will be fulfilled from the contractor's location in Conshohocken, Pennsylvania. The contract represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract with the...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $6,008.95 on October 16, 2025, for the supply of Rabavert rabies vaccine with diluents. This firm fixed price, non-set-aside contract is funded by the Defense Logistics Agency's Medical Supply Chain and carries an ultimate completion date of October 17, 2025. The order will be fulfilled at AmerisourceBergen's Conshohocken facility and represents a...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of Rabavert rabies vaccine with diluents. This $6,287.40 firm fixed-price delivery order is a non-set-aside contract with an ultimate completion date of September 30, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order award from the Defense Logistics Agency (DLA) on April 22, 2025, for the supply of IMOVAX Rabies Vaccine Vials. This firm fixed-price delivery order, valued at $2,673.00, is scheduled for completion by April 23, 2025, and will be performed at the awardee's Conshohocken facility. The award represents a non-set-aside, competitively awarded contract typical of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $29,341.20 to AmerisourceBergen Drug Corp for Rabavert Rabies Vaccine with diluents, with performance in Conshohocken, Pennsylvania. This firm fixed-price delivery order, awarded on August 15, 2025, represents a non-competitive procurement and is scheduled for completion by August 18, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal medical...
- The Defense Logistics Agency awarded a $10,479 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Rabavert rabies vaccine with diluents, with an ultimate completion date of September 24, 2025. This competitively awarded, non-set-aside contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency (DLA) awarded a $20,290 firm fixed price delivery order to AmerisourceBergen Drug Corp for Rabavert rabies vaccine with diluents, with performance in Conshohocken, Pennsylvania and an ultimate completion date of October 23, 2025. This non-set-aside competitive award was issued on October 22, 2025, and represents a child contract under AmerisourceBergen's larger federal pharmaceutical supply agreements with the DLA. AmerisourceBergen Drug Corp, a major...
- The Defense Logistics Agency awarded a $16,766.40 firm fixed price delivery order to AmerisourceBergen Drug Corp for Rabavert rabies vaccine with diluents, with performance at the contractor's Conshohocken, Pennsylvania facility. The order, issued September 16, 2025, with completion targeted for September 17, 2025, represents a competitive award with no set-aside designation. This delivery order falls under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW2FQDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $1,962.10 by the Defense Logistics Agency (DLA) on July 5, 2025, for the supply of Rabavert rabies vaccine with diluents. The contract carries a firm fixed price structure with no set-aside designation, indicating it was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of July 7, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. The rabies vaccine delivery order supports the Defense Health Agency and broader military healthcare system requirements for critical immunological products. AmerisourceBergen's established relationship with DLA demonstrates the company's capability to fulfill federal medical procurement needs through multiple therapeutic domains, with a portfolio encompassing specialty medications, vaccines, and medical supplies. The rapid completion timeline reflects the urgent nature of vaccine procurement for military personnel and readiness operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 7/5/25 |